| Literature DB >> 25308320 |
Gregory B Stanton1, Shawn J Kohler, Jennifer Boklweski, Judy L Cameron, William T Greenough.
Abstract
We used confocal microscopy and immunohistochemistry (IHC) to look for new cells in the motor cortex of adult macaque monkeys that might form the cellular bases of improved brain function from exercise. Twenty-four female Macaca fascicularis monkeys divided into groups by age (10-12 years, 15-17 years), postexercise survival periods, and controls, received 10 weekly injections of the thymidine analog, bromodeoxyuridine (BrdU) to mark new cells. Sixteen monkeys survived 15 weeks (5 weeks postexercise) and 8 monkeys survived 27 weeks (12 weeks postexercise) after initial BrdU injections. Additionally, five Macaca mulatta female monkeys (∼5.5-7 years) received single injections of BrdU and survived 2 days, 2 weeks, and 6 weeks after BrdU injections. Neural and glial antibodies were used to identify new cell phenotypes and to look for changes in proportions of these cells with respect to time and experimental conditions. No BrdU(+) /DCx(+) cells were found but about 7.5% of new cells were calretinin-positive (Cr(+) ). BrdU(+) /GABA(+) (gamma-aminobutyric acid) cells were also found but no new Cr(+) or GABA(+) cells colabeled with a mature neuron marker, NeuN or chondroitin sulfate antibody, NG2. The proportion of new cells that were NG2(+) was about 85% for short and long survival monkeys of which two, newly described perivascular phenotypes (Pldv and Elu) and a small percentage of pericytes (2.5%) comprised 44% and 51% of the new NG2(+) cells, respectively. Proportions of NG2(+) phenotypes were affected by post-BrdU survival periods, monkey age, and possibly a postexercise sedentary period but no direct effect of exercise was found.Entities:
Keywords: BrdU; Olig2; PDGFrβ; calretinin; confocal microscopy; exercise; pericytes; polydendrocytes
Mesh:
Substances:
Year: 2014 PMID: 25308320 PMCID: PMC4354441 DOI: 10.1002/cne.23693
Source DB: PubMed Journal: J Comp Neurol ISSN: 0021-9967 Impact factor: 3.215
Figure 1Timeline diagrams of monkey groups. A: Monkeys that received a single BrdU injection and survived short time intervals before perfusion (down arrows). B: Runner and sedentary control monkeys that received 10 weekly BrdU injections and survived 5 or 17 weeks after the injection period.
Primary Antibodies Used for Immunohistochemistry
| Antibody | Immunogen | Manufacturer catalog #, host species, mono- vs. polyclonal, and RRID # | Dilution used |
|---|---|---|---|
| Bromodeoxyuridine (BrdU) | BrdU incorporated into DNA | Accurate Chemical - AbD Serotec #T0030, rat monoclonal, RRID #AB609566 | 1:500 |
| Calbindin (Cb) | Recombinant mouse calbindin | Chemicon-Millipore #AB1778, rabbit polyclonal, RRID #AB 2068348 | 1:200 |
| Calretinin (Cr) | Recombinant rat calretinin | Chemicon-Millipore #AB5054, rabbit polyclonal, RRID #AB 2068506 | 1:500 |
| Collagen IV (COL IV) | Collagen Type IV extracted and purified from mouse tumor | Chemicon-Millipore #AB756P, rabbit polyclonal, RRID #AB2276457 | 1:300 |
| Doublecortin (DCx) | Synthetic peptide to human doublecortin corresponding to aa CysYLPLSLDDSD SLGDSM-free acid | Cell Signaling Technology #4604x, rabbit polyclonal, RRID # AB561007 | 1:400 |
| Gamma amino butyric acid (GABA) | γ-aminobutyric acid (GABA) conjugated to BSA | Sigma-Aldridge #A2052, rabbit polyclonal, RRID #AB477652 | 1:2000 |
| Glia fibrillary acidic protein (GFAP) | Purified bovine GFAP | Chemicon-Millipore #AB5804, Rabbit polyclonal, RRID #AB2109645 | 1:1600 |
| Iba1 - (Ionized calcium binding adaptor molecule 1) | Synthetic peptide corresponding to C-terminus aa NA′-PTGPPAKKAISELP-C′ | Wako Chemicals USA, Inc. #019-19741, rabbit polyclonal, RRID #AB839504 | 1:200 |
| Neural-glial antibody 2 (NG2) 9.2.27 | Human M14 melanoma cell extract | Gift from Dr. Ralph Reisfeld, Scripps Research Institute, mouse monoclonal | 1:1500 |
| Neuron specific nuclear protein (NeuN) | Purified cell nuclei from mouse brain | Chemicon-Millipore #AB377, mouse monoclonal, RRID # AB94966 | 1:500 |
| Oligodendrocyte transcription factor 2 (Olig2) Rabbit anti-human | Synthetic peptide in portion of C-terminus of Human Olig2, aa 236-285 | IBL-America #18953, rabbit polyclonal, RRID # AB494617 | 1:100 |
| Platelet derived growth factor receptorß (PDGFrß) | Synthetic peptide, aa 1086-1106 from C-terminus of human PDGFrß | Epitomics -ABCAM #32570, rabbit monoclonal, RRID# AB777165. | 1:400 |
| S100ß | recombinant S-100ß | Swant 36 (discontinued),r bovine polyclonal | 1:4000 |
Figure 2New NG2 cells classified as pericytes (A–D) and Elu cells (E–J). A1,2: New pericytes embedded in the walls of NG2-rich vessels. Cell processes of these cells are confined to the vessel walls. An unlabeled pericyte profile can be seen below the labeled cell in 1. Asterisks mark vessel lumens in this and other images of the figure. B: A new pericyte merges with the vessel wall. Longitudinal and transverse filaments in vessel wall typical of pericytes are highlighted by NG2 and PDGFrβ antibodies. C: New pericyte cell on vessel surface. PDGFrβ+ label is concentrated along the vessel lumen and transverse pericyte processes are visible. D: New pericyte on vessel surface lies internal to Col IV, a component of the basement membrane. E: Elu cell protruding into a small vascular space. The endothelial wall opposite the cell is labeled by tomato lectin. The vascular space was continuous with a larger, bifurcating vessel that would be invisible except for labeling of the vessel wall by tomato lectin. The vessel lumen is marked with an asterisk. F: Two Elu cells seen in three optical slices. Channels that make up the middle slice appear in the lower tier of images. The upper cell bulges into a small vascular space that is marked with tomato lectin. G: A pair of Elu cells labeled with Olig2. A small, branching process extends upward from the right cell. H–J: Three projection slices of an Elu cell at the branch point of a small vessel from a larger one (asterisk in I). Cell processes (arrowheads in H, J2) labeled with NG2 and PDGFrβ antibodies extend transversely and longitudinally along the vessel wall and into the brain parenchyma. PDGFrβ label was most concentrated next to the endothelial cell wall that is labeled with tomato lectin. Note that the nucleus of the cell is external to the endothelial wall. Three of four channels that make up merged images in H, I4, and J are shown in I1-3. J1, 3 are orthogonal images of J2. Scale bars = 10 μm.
Figure 4Two NG2+ cells showing vacuoles and tube-like passages within processes labeled with PDGFrβ antibody. A: A merged, projection stack image of the cells (1,2). Two of many NG2+- rich processes that have little or no PDGFrβ+ are marked with arrows (also in B3). Two processes are densely colabeled with PDGFrβ+ and contain tube-like passages (single and double arrowheads; also in B1,4; D3) that extend the length of the processes and end in large expansions (asterisks). The large, central process appears to be a complex of processes from cells 1 and 2, whereas the shorter, horizontal process arises from cell 1 alone. B1–4: Single xy slices, showing a central passage (arrowheads) extending between the perinuclear regions of cells 1 and 2. Note the budding of a tube-like passage in the horizontal process in B1. Smaller vacuoles are seen in B2. C: Side view reconstruction of the two cells showing the two PDGFrβ-labeled processes (other processes were digitally removed). The open arrowhead shows an alignment artifact (also seen in D1–3) between the two stacks that make up images A and C. D1–3: Single yz slices showing the central (arrowhead) and horizontal (double arrowheads) passages seen in A. The central tube ends in an expansion (asterisks). The inset in 2 shows the expansion in optical slices that are adjacent to the one in 2 (a, xy; b, yz; c, xz slice planes). Note that the expansion is enclosed within the process. Scale bars = 10 μm.
Figure 3Polydendrocytes (Pld) and polydendritic perivascular cells (Pldv) are characterized by multiple, complex branches. A: A pair of new Pld cells with closely paired nuclei indicating recent cell division. PDGFrβ labeling was seen near the cell body and in one process of the lower cell but these cells were not perivascular. B: Two Pldv cells with thick, branching dendrites enclosing a small vascular space (asterisk). Only the lower cell is new born and sparsely labeled with Olig2. C,D: A new Pldv cell partially enclosing a small vessel (C4, asterisk; arrowheads in C3 and orthogonal slices D1,2). The projection stack of sections in D3 shows multiple branching processes of the cell that obscure the vessel. E,F: A pair of Pldv cells and adjacent vessel shown in two slice planes. The vessel lumen (asterisks) can be seen in single sections (E1,F1) but is obscured by the processes of the cell in maximum projection stacks (E2,F2). The approximate plane of section for E1 can be seen as line in F1. G–I: A Pldv cell with unstained passage (arrow) in a cell process extending to the left and clefts (arrowheads) that are continuous with adjacent vessel. G–H: Two optical slices through the cell showing NG2 and combined BrdU and NG2 channels. I: A z projection stack of all optical slices through the cell. The arrowhead points to a cleft that opens into the lumen of the vessel seen in H1. Scale bars = 10 μm.
Cell Pairs
| Monkey | BrdU# | % BrdU |
|---|---|---|
| 2 d | 80 | 36 |
| 2 d | 46 | 15 |
| 2 w | 66 | 15 |
| 6 w | 75 | 11 |
| 6 w | 79 | 06 |
| mean/SEM | 17 ± 5 | |
| OR | 34 | 09 |
| YC | 31 | 06 |
| YR | 30 | 10 |
| YRS | 18 | 05 |
| YRS | 40 | 03 |
| mean/SEM | 07 ± 1 |
Percentages of BrdU+ cell pairs with respect to BrdU cell totals from a single IHC batch that processed sections for BrdU, NG2, and Olig2 antibodies using tissue from monkeys with single BrdU injections and short survivals after BrdU (top) and monkeys with multiple BrdU injections and long survivals after BrdU (bottom). 2 d, 2 day; 2 w, 2 week; 6 w, 6 week; OR, Older runners, YC, younger controls, YR, younger runners, YRS, younger run-stops.
Figure 5BrdU+ cells labeled with Cr, GABA, and glial antibodies. A: Single optical sections in the xy and xz planes through a multipolar BrdU+/Cr+ cell. B: A bipolar, BrdU+/Cr+ cell and single-labeled BrdU+ cell. The bipolar cell is closely apposed to the larger NeuN+ neuron. Inset shows the impression made by the Cr+ cell. C: Two BrdU+/GABA+ satellite cells juxtaposed on a larger NeuN neuron. A third, BrdU-/GABA+ cell is also seen. Note all GABA+ cells are immature but are comparable in size and in juxtaneuronal position to the Cr+ cell seen in B. D: Two BrdU+ neurons that are satellite cells on NeuN+ and NeuN+/Cr+ cells. E: Percentages of BrdU+ counted as neuronal satellites in a series of exercise monkeys. OC, older control; OR, older runner; ORS, older run-stop; YC, younger control; YR, younger runner; YRS, younger run-stop. F: BrdU+/NG2+ cell closely applied to a Cr+ cell. G: NG2 and s100β antibodies label separate populations of cells. H: NG2 and Iba1 label separate populations of cells. Scale bars = 10 μm.
New Cell Phenotypes in Monkeys With Short Survivals After Single BrdU Injections
| A. | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Post-Brdu survival | NG2+ cells | NG2− cells | NOT perivasc | Combined cell types | |||||||
| Per-Elu | Pldv | Pld | NG2+ unk | perivasc | Total NG2+ | All NG2+ perivasc | All perivasc | NG2+ multi-branch | NG2+ NOT multi-branch | ||
| 2 d | 43 | 5 | 18 | 28 | 1 | 6 | 94 | 48 | 49 | 23 | 71 |
| 2 d | 40 | 0 | 10 | 40 | 3 | 7 | 90 | 40 | 43 | 10 | 80 |
| 2 w | 48 | 6 | 21 | 8 | 5 | 13 | 83 | 54 | 59 | 28 | 56 |
| 6 w | 16 | 29 | 34 | 9 | 3 | 10 | 86 | 44 | 48 | 63 | 24 |
| 6 w | 22 | 13 | 34 | 6 | 3 | 19 | 74 | 35 | 38 | 48 | 28 |
A: Percentages of BrdU+ cell totals for NG2+ and NG2− cell types and cell combinations from monkeys with single BrdU injections and short survivals after BrdU. Cell counts are in parentheses and italicized. 2 d, 2 day; 2 w, 2 week; 6 w, 6 week; a, NG2+ unknown (not perivascular, not multi-branched); b, Per-Elu and Pldv; c, Per-Elu, Pldv, and NG2− perivascular; d, Pldv and Pld; e, Per-Elu, and NG2+ unk. B: Estimated mean percentages and ranges of new cell phenotypes and combinations based on binomial regression modeling.
New Cell Phenotypes in Monkeys With Long Survivals After Multiple BrdU Injections
| A. | |||
|---|---|---|---|
| Cell type or combination | Lower | Estimate | Upper |
| All NG2%BrdU | 83% | 85% | 87% |
| PerElu | 24% | 27% | 30% |
| Pldv | 20% | 23% | 26% |
| Pld | 25% | 27% | 30% |
| NG2+ unknown | 5% | 7% | 8% |
| NG2− perivascular | 3% | 4% | 5% |
| NG2− NOT perivascular | 9% | 11% | 13% |
| NG2+ perivascular combined | 48% | 51% | 54% |
| All perivascular | 51% | 54% | 57% |
| Multibranched | 48% | 51% | 54% |
| NOT Multibranched | 31% | 34% | 37% |
A: Estimated mean percentages and ranges for new cell phenotypes and cell combinations based on binomial regression modeling. B: Above, mean percentages of BrdU+ cell totals and SEMs for NG2+ and NG2− cell types and cell combinations from each group of experimental exercise monkeys. Cell counts are in parentheses and italicized. Below, P values of significant differences in paired comparisons of exercise groups. Calculated P-values correspond to comparing the log odds ratios resulting from binomial regression analysis.
P = 0.05 −0.01
P > 0.01. OC, older control group; OR, older runner group; ORS, older run-stop group; YC, younger control group; YR, younger runner group; YRS, younger run-stop group; n = 4 except YC where n = 3.
Figure 6A: Estimated mean percentages, relative to BrdU+ cell totals, of individual and combined NG2+ and NG2– cell types from monkeys that survived short periods after single BrdU injections. B: Estimated mean percentages of individual and combined NG2+ and NG2– cell types from monkeys that survived long periods after multiple BrdU injections. C: Relative proportions of adult born (BrdU+) cell types defined morphologically and immunohistochemically. The cumulative means listed in Table2 were used to construct proportionate wedges of the chart. BrdU+/NG2+ cells are represented by gray wedges. Per cells (2.5%) are shown separately from the Per-Elu group. BrdU+/NG2– cells (perivascular, non-perivascular) appear as white wedges with a separate wedge for Cr+ cells (7–8%) derived from the total non-perivascular group in Table2. All adult born perivascular cells appear in wedge segments between the arrowheads. Satellite cells comprising about 34% of all BrdU+ cells are not shown. NG2+ unk: unknown, not perivascular, not multibranched new cells; NG2– unk: not perivascular new cells.